Celsion Brings In GCP Auditor Following FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Celsion predicts that by fall it will be in total compliance with issues FDA raises in a May 7 warning letter
You may also be interested in...
Device Firms Struggling With Trial Monitoring Could Receive BIMO Guidance
FDA's Division of Bioresearch Monitoring will convene a June meeting of industry stakeholders to commence development of a best practices guidance for medical device clinical trial monitoring
Boston Scientific To Market Celsion’s Prolieve BPH Device Immediately
Boston Scientific will promote Celsion's Prolieve microwave urethroplasty system as a less-painful alternative to existing treatments for benign prostatic hyperplasia (BPH), following FDA approval Feb. 19
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.